Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: genzyme-corporation.
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
43 filings
$13.9M on those filings
Taxation/Internal Revenue Code
TAX
36 filings
$12.4M on those filings
Copyright/Patent/Trademark
CPT
33 filings
$10.8M on those filings
Budget/Appropriations
BUD
27 filings
$10.4M on those filings
Medical/Disease Research/Clinical Labs
MED
9 filings
$6.3M on those filings
Trade (domestic/foreign)
TRD
9 filings
$2.3M on those filings
Food Industry (safety, labeling, etc.)
FOO
1 filing
$20K on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
112th Congress
FAST Act
9 filingsthrough 2012
S. 1695110th CongressBiologics Price Competition and Innovation Act of 20079 filingsthrough 2008
H.R. 1078114th CongressFood and Drug Administration Safety Over Sequestration Act of 20158 filingsthrough 2016
H.R. 1130114th CongressChronic Kidney Disease Improvement in Research and Treatment Act of 20158 filingsthrough 2016
H.R. 1376114th CongressPatient Choice Act of 20158 filingsthrough 2016
H.R. 1416114th CongressCancer Patient Protection Act of 20158 filingsthrough 2016
H.R. 1600114th CongressPatients' Access to Treatments Act of 20158 filingsthrough 2016
H.R. 2114th CongressMedicare Access and CHIP Reauthorization Act of 20158 filingsthrough 2016
H.R. 696114th CongressTo amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.8 filingsthrough 2016
H.R. 744114th CongressMedical Innovation Act of 20158 filingsthrough 2016
H.R. 790114th CongressCompassionate Freedom of Choice Act of 20158 filingsthrough 2016
H.R. 880114th CongressAmerican Research and Competitiveness Act of 20158 filingsthrough 2016
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
17 filingsthrough 2014
Mary McgraneGenzyme CorporationCovered position: Senior Vice President14 filingsthrough 2012
